排名前五的靶点	数量

DNase I(脱氧核糖核酸酶1)	4
APP(β-淀粉状蛋白A4)	3
IL-4Rα(白细胞介素-4受体α亚基)	2
EGFR C797S x EGFR L858R x EGFR T790M x EGFR-Ex19del	2
CTNNB x Wnt蛋白	1

关联

项与 Yonsei University 相关的药物

Tirvalimogene Teraplasmid

靶点-

作用机制

免疫刺激剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

ICM-203

靶点

NKX3-2

作用机制

NKX3-2 modulators [+1]

在研机构

ICM Co. Ltd. [+2]

原研机构

ICM Co. Ltd.

在研适应症

膝关节炎 [+2]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

DA-4505

靶点

AHR

作用机制

AHR拮抗剂

在研机构

Yonsei University [+1]

原研机构

Yonsei University [+1]

在研适应症

局部晚期恶性实体瘤 [+1]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

1,544

项与 Yonsei University 相关的临床试验

NCT07260721

/ Not yet recruitingN/AIIT

Investigator-initiated Trial to Evaluate the Performance and Utility of a Single-lead Electrocardiogram Patch-based Telemetry System in Patients Requiring In-hospital Telemetry Electrocardiogram Monitoring During Hospitalization

"This investigator-initiated, prospective, single-center clinical study evaluates the performance and clinical utility of a single-lead electrocardiogram (ECG) patch-based telemetry system for hospitalized patients who require in-hospital telemetry ECG monitoring. The system integrates real-time centralized surveillance (MEMO-Cue) with post-hoc analytic review (MEMO-Care) using ECG signals recorded by the MEMO Patch M, aiming to enable timely recognition of clinically important arrhythmias and to inform treatment decisions under routine inpatient conditions.
Adults (≥19 years) indicated for continuous ECG monitoring during admission are enrolled after written informed consent, with a planned sample size of 100 to yield approximately 90 evaluable participants (10% anticipated dropout). The design does not include randomization or blinding. Study procedures include a screening visit (eligibility and baseline data), an inpatient monitoring period of at least 12 hours and up to 8 days with simultaneous MEMO-Cue monitoring and MEMO Patch M recording, and an end-of-visit assessment when MEMO-Care analytic results become available. Concomitant therapies deemed clinically necessary are permitted and documented, and adverse events are prospectively assessed.
Clinical utility endpoints quantify care impact and timeliness: (1) rate of treatment plan changes (e.g., initiation or modification of anticoagulants or antiarrhythmic drugs, cardioversion scheduling, device implantation, or other actions); (2) time to recognition (days) of major arrhythmias-atrial fibrillation (AF), ventricular tachycardia (VT), pause, ventricular premature complex (VPC), and supraventricular tachycardia (SVT)-based on MEMO-Cue alarms or MEMO-Care results with objective confirmation; (3) reduction ratio in recognition time when identified earlier by MEMO-Cue versus MEMO-Care; and (4) proportion of participants with shortened recognition time by MEMO-Cue.
Clinical performance endpoints assess detection characteristics and agreement between MEMO-Cue alarms and MEMO-Care findings: (1) clinical sensitivity (true positive / [true positive + false negative]); (2) precision, i.e., positive predictive value (true positive / [true positive + false positive]); and (3) positive concordance rate (proportion of MEMO-Care-detected arrhythmias alerted by MEMO-Cue). Safety is captured as treatment-emergent adverse events after device application, including device-related skin reactions, detachment, or signal dropouts, with severity graded per NCI-CTCAE v5.0 and relationship to device recorded.
By characterizing real-time patch-based telemetry alongside analytic review and its influence on diagnostic timing and management, the study aims to generate practical evidence supporting feasibility, reliability, and workflow compatibility of single-lead patch telemetry for in-hospital ECG monitoring.

开始日期2025-12-01

申办/合作机构

Yonsei University

NCT07238972

/ Not yet recruiting临床4期IIT

Impact of Postoperative Intravenous Iron Supplementation on the Incidence of Long-term Anemia in Patients Undergoing Cardiac Surgery

Postoperative anemia is highly prevalent among patients undergoing cardiac surgery and is associated with delayed functional recovery, increased morbidity, and impaired long-term outcomes. Preoperative iron deficiency is common in this population and contributes to inadequate erythropoietic recovery after surgery. Functional iron deficiency frequently develops even in patients without preoperative deficiency due to blood loss, hemodilution, and inflammation-mediated disruption of iron homeostasis. Despite this clinical burden, standardized strategies for postoperative anemia management have not been established.
This prospective, randomized, double-blind, placebo-controlled clinical trial evaluates whether early postoperative intravenous iron supplementation improves long-term anemia outcomes in patients undergoing cardiac surgery with cardiopulmonary bypass. Adult patients with preoperative anemia (hemoglobin <13 g/dL) or iron deficiency (ferritin <100 ng/mL or transferrin saturation <20%) will be screened. Eligible participants with postoperative day (POD) 1 hemoglobin <10 g/dL will be randomized in a 1:1 ratio to receive either ferric derisomaltose (20 mg/kg, maximum 1,000 mg) or a matched placebo administered intravenously over 30 minutes on POD 1. All perioperative management outside the intervention follows current institutional standards.
The primary outcome is the incidence of anemia at 6 months following surgery. Secondary outcomes include perioperative hemoglobin trends, functional recovery assessed by cardiopulmonary exercise testing and the 6-minute walk test at 6 months, transfusion requirements, postoperative complications including MAKE-90 and STS major morbidity, and changes in biomarkers of erythropoiesis and iron metabolism (erythroferrone, erythropoietin, hepcidin, and iron profile). Blood samples for biomarker analysis are collected at predefined perioperative timepoints.
Ferric derisomaltose allows high-dose single-session iron repletion with a favorable safety profile and minimal risk of anaphylaxis when administered slowly. Prior studies in cardiac surgery and heart failure populations support its efficacy and safety at doses up to 20 mg/kg. The intervention is expected to facilitate erythropoietic recovery, reduce the duration of postoperative anemia, and improve long-term functional status. The trial aims to generate evidence to inform postoperative anemia management strategies in cardiac surgery patients.

开始日期2025-12-01

申办/合作机构

Yonsei University

NCT07265128

/ Not yet recruiting临床4期IIT

Effect of Remimazolam on Delirium After Cardiac Surgery: Randomized Controlled Trial With Midazolam

"Postoperative delirium is a common and serious complication following cardiac surgery, particularly among older adults who require intensive care. Its incidence is reported to range between 20% and 70% after cardiopulmonary bypass (CPB), and has been associated with prolonged hospitalization, increased medical costs, higher morbidity and mortality, and long-term cognitive decline. Benzodiazepines are frequently used during anesthetic induction in cardiac surgery due to favorable hemodynamic stability, although multiple clinical guidelines have recommended limitation of benzodiazepine exposure because of concerns for delirium. However, robust clinical evidence in cardiac surgery remains limited.
Midazolam is currently the most commonly administered benzodiazepine in this setting, though metabolism through hepatic pathways and accumulation of active metabolites may increase the risk of postoperative delirium, especially in older patients and those with organ dysfunction. Remimazolam, a recently approved benzodiazepine, undergoes rapid hydrolysis by plasma esterases and demonstrates predictable pharmacokinetic properties with a markedly shorter context-sensitive half-time compared to midazolam. These pharmacologic features suggest a potentially reduced impact on postoperative delirium risk. Despite this rationale, no randomized controlled trial has evaluated the effect of remimazolam versus midazolam on delirium after CPB-assisted valve surgery.
This randomized double-blind controlled trial aims to determine whether remimazolam reduces the incidence of postoperative delirium compared with midazolam in patients aged ≥65 years undergoing valve surgery with CPB. Eligible participants will be randomized in a 1:1 ratio to receive either remimazolam or midazolam for anesthetic induction according to a computer-generated allocation sequence. All other anesthetic management will follow standardized institutional protocols, including depth of anesthesia monitoring. Delirium assessment will be performed three times daily in the intensive care unit using Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or Intensive Care Delirium Screening Checklist (ICDSC) and twice daily on the ward using 3-Minute Diagnostic Interview for CAM (3D-CAM) for four postoperative days.
The primary endpoint is the incidence of delirium within four postoperative days. Key secondary outcomes include in-hospital or 30-day mortality and a composite of major postoperative complications. A total of 300 patients (150 per group) will be enrolled to provide 90% statistical power to detect the hypothesized difference in delirium risk between groups, accounting for a 10% dropout rate. Findings from this study are expected to provide high-quality evidence regarding the comparative impact of remimazolam and midazolam on postoperative delirium and may inform anesthetic strategy selection in high-risk cardiac surgical populations."

开始日期2025-12-01

申办/合作机构

Yonsei University

100 项与 Yonsei University 相关的临床结果

登录后查看更多信息

0 项与 Yonsei University 相关的专利（医药）

登录后查看更多信息

40,971

项与 Yonsei University 相关的文献（医药）

2026-12-01·Nano-Micro Letters

Chirality-Induced Suppression of Singlet Oxygen in Lithium–Oxygen Batteries with Extended Cycle Life

Article

作者: Jang, Dohyub ; Kim, Youngsin ; Kim, Dong Ha ; Chae, Kyunghee ; Oh, Yookyeong ; Kim, Hyuk-Joon ; Moon, Jooho ; Kang, Kisuk ; Son, Jaehyun ; Marques Mota, Filipe ; Han, Jeong Woo ; Kim, Youngbi ; Lee, Hyun Jeong ; Hahn, Hosik

Abstract:

Lithium–oxygen (Li–O2) batteries are perceived as a promising breakthrough in sustainable electrochemical energy storage, utilizing ambient air as an energy source, eliminating the need for costly cathode materials, and offering the highest theoretical energy density (~ 3.5 kWh kg–1) among discussed candidates. Contributing to the poor cycle life of currently reported Li–O2 cells is singlet oxygen (1O2) formation, inducing parasitic reactions, degrading key components, and severely deteriorating cell performance. Here, we harness the chirality-induced spin selectivity effect of chiral cobalt oxide nanosheets (Co3O4 NSs) as cathode materials to suppress 1O2 in Li–O2 batteries for the first time. Operando photoluminescence spectroscopy reveals a 3.7-fold and 3.23-fold reduction in 1O2 during discharge and charge, respectively, compared to conventional carbon paper-based cells, consistent with differential electrochemical mass spectrometry results, which indicate a near-theoretical charge-to-O2 ratio (2.04 e−/O2). Density functional theory calculations demonstrate that chirality induces a peak shift near the Fermi level, enhancing Co 3d–O 2p hybridization, stabilizing reaction intermediates, and lowering activation barriers for Li2O2 formation and decomposition. These findings establish a new strategy for improving the stability and energy efficiency of sustainable Li–O2 batteries, abridging the current gap to commercialization.

2026-12-01·Nano-Micro Letters

Regularly Arranged Micropore Architecture Enables Efficient Lithium-Ion Transport in SiOx/Artificial Graphite Composite Electrode

Article

作者: Lim, Jaejin ; Lee, Mingyu ; Kang, Dongyoon ; Lee, Hongkyung ; Lee, Yong Min ; Choi, Seungyeop ; Bak, Cheol

Abstract:

To enhance the electrochemical performance of lithium-ion battery anodes with higher silicon content, it is essential to engineer their microstructure for better lithium-ion transport and mitigated volume change as well. Herein, we suggest an effective approach to control the micropore structure of silicon oxide (SiOx)/artificial graphite (AG) composite electrodes using a perforated current collector. The electrode features a unique pore structure, where alternating high-porosity domains and low-porosity domains markedly reduce overall electrode resistance, leading to a 20% improvement in rate capability at a 5C-rate discharge condition. Using microstructure-resolved modeling and simulations, we demonstrate that the patterned micropore structure enhances lithium-ion transport, mitigating the electrolyte concentration gradient of lithium-ion. Additionally, perforating current collector with a chemical etching process increases the number of hydrogen bonding sites and enlarges the interface with the SiOx/AG composite electrode, significantly improving adhesion strength. This, in turn, suppresses mechanical degradation and leads to a 50% higher capacity retention. Thus, regularly arranged micropore structure enabled by the perforated current collector successfully improves both rate capability and cycle life in SiOx/AG composite electrodes, providing valuable insights into electrode engineering.

2026-04-01·BIOMATERIALS

Hydrogel-based piezoelectric materials and devices for implantable bioelectronics

Review

作者: Kim, Sang-Woo ; Choudhury, Saswat ; Wang, Zhong Lin

Next-generation biomedical devices increasingly require integrated energy harvesting and miniaturized electronic components to achieve self-sustaining operation without external power sources. However, most currently available systems remain rigid and bulky, impeding effective mechanical and biological interfacing with soft tissues. Hydrogels, with their high water content, tunable elasticity, and excellent biocompatibility, have emerged as ideal candidates for developing conformal and tissue-compliant electronics. To overcome the limitations of battery-powered implants, recent studies have focused on harvesting biomechanical energy - particularly via piezoelectric nanogenerators (PENGs) - as a sustainable alternative. The integration of PENGs into hydrogel matrices has led to the emergence of piezoelectric hydrogels (PHs), a novel class of soft, biocompatible, and self-powered biomaterials. These hybrid materials combine the mechanical adaptability of hydrogels with the energy conversion capabilities of piezoelectric materials, enabling new paradigms in implantable and wearable electronics. This review presents a comprehensive overview of PHs, including piezoelectric material classifications (ceramics, polymers, nanocomposites), fabrication strategies of natural and synthetic PHs, and their device-level performance under physiological conditions. Furthermore, we discuss the application of PHs in skin wound healing, peripheral nerve regeneration, and the repair of bone and cartilage tissues. Finally, we provide a future outlook emphasizing the need for mechanistic insights, improved output performance, and standardized in vivo evaluations to accelerate the clinical translation of PH-based self-powered bioelectronics.

项与 Yonsei University 相关的新闻（医药）

2025-12-05

·壮士维智慧干细胞

人胚胎干细胞疗法在帕金森病治疗中取得突破，临床数据显示安全性良好

帕金森病是一种神经退行性疾病，目前，国内外还没有很好的方法能干预这一疾病。以干细胞为代表的新型生物疗法，成为帕金森病治疗的一个重要研究新方向，并逐渐在临床上显露其价值，给患者以新的希望。帕金森病是全球第二大神经退行性疾病，病程长、致残率高，随着人口的年龄逐渐增长，患病率也呈逐渐上升的趋势。《中国帕金森病报告2025》指出，中国现存的帕金森病患病人数超过500万例。值得注意的是，近30年间，包括发病率、患病率和死亡率等在内的与帕金森病相关的疾病负担指标，总体上均呈现快速上升趋势。帕金森病治疗现状：临床不尽之需帕金森病的典型病理特征表现为中脑黑质内多巴胺能神经元发生死亡，临床上表现为静止性震颤、肌强直、运动迟缓和姿势平衡障碍等运动症状，以及嗅觉障碍、睡眠障碍、自主神经功能障碍等非运动症状。目前，帕金森病的治疗首选是药物替代疗法。左旋多巴等药物虽然可以改善患者症状，但是随着病程发展，多巴胺能神经元损失越来越多，药物疗效逐渐减退并出现不良反应。此外，脑深部刺激手术（DBS）也可以针对部分患者通过手术向患者脑中植入电极来控制运动症状。不过，所有这些都还无法真正满足临床的需求。无论是药物还是手术，主要是对症治疗，只能改善患者的临床表现，并不能阻止病情的发展，更无法实现治愈。以干细胞为代表的新型生物疗法应运而生，成为帕金森病治疗的一个重要研究方向。干细胞畅想：能否根本解决帕金森难题干细胞治疗帕金森病并非一个新概念。早在20世纪80年代，瑞典隆德大学的科学家就提出“细胞替代疗法”的概念。他们将流产胎儿腹侧中脑来源的多巴胺能神经元立体定向移植给帕金森病患者，用于晚期帕金森病的治疗。随后，其他欧美国家也开展了类似研究，结果显示，部分帕金森患者的生活质量在移植后能得到显著提升。不过，从胚胎的脑组织取样，数量少，有伦理争议，显然不是长久之计。因此，科学家将目光转向具有增殖、自我更新和多向分化潜能的干细胞。干细胞的特点就是可以不断自我更新，并且根据人们的需要，分化为不同种类的细胞。科学家们考虑，如果能诱导干细胞转化成多巴胺能神经元，补充给帕金森患者，让这些健康的神经元在患者体内持续地产生多巴胺，就有可能根本上解决帕金森的治疗难题。近日，高丽大学安岩医院、延世大学等单位联合一项发表在《Cell》的突破性研究显示：利用人胚胎干细胞（hESC）衍生的高纯度多巴胺能祖细胞（A9-DPC），成功完成了帕金森病（PD）患者的1/2a期临床试验，结果表明，这种细胞疗法不仅安全性良好，还能显著改善中重度患者的运动症状，为帕金森病的细胞替代治疗提供了关键证据。 01 研究设计：单中心、剂量递增的第一步这项1/2a期的临床试验，旨在评估人胚胎干细胞衍生高纯度多巴胺能祖细胞（A9-DPC）的安全性和初步疗效。研究采用单中心、开放标签、剂量递增设计，纳入12名中重度帕金森病患者。参与者被分为两组：低剂量组（6人）：每侧壳核移植315万个A9-DPC；高剂量组（6人）：每侧壳核移植630万个A9-DPC。移植后，患者接受长达12个月的免疫抑制治疗，以预防排斥反应。研究的主要终点是安全性（不良事件发生率），次要终点包括运动症状改善和细胞存活/功能。 A9-DPC移植后临床结局的纵向变化 02 临床结果：安全性与有效性双突破 1. 安全性：无严重不良反应，细胞相关风险为零 12个月随访中，32例不良事件（AE）均与A9-DPC无关，其中1例为手术相关的无症状颅内出血，3例可能与免疫抑制有关（短暂高钾血症、新发糖尿病、无症状血小板减少），但均可控或自愈。无肿瘤形成、细胞过度增殖或免疫介导炎症——这是细胞治疗最担心的安全问题，在本研究中完全未出现。这是关键的第一步，证明了A9-DPC移植的安全性，为后续研究奠定了基础。 2. 有效性：运动症状显著改善，剂量依赖性明显关期运动症状（未服药状态）是帕金森病最影响生活质量的症状。12个月后，结果显示：低剂量组MDS-UPDRS III关期评分（帕金森病评定量表）较基线下降12.7分（改善率约21%）；高剂量组下降15.5分（改善率约26%），且通过线性混合效应模型分析，高剂量组的改善更具统计学意义（p=0.019）。 Hoehn-Yahr分期（衡量疾病严重程度）也显示：低剂量组从3.7期降至2.7期，高剂量组从3.8期降至2.2期——意味着部分患者从中重度回归中度。此外，日常非运动症状（如睡眠、情绪）和生活质量（PDQ-39评分）也有显著改善，而认知功能（MMSE/MoCA）保持稳定，说明疗法未影响认知。 3. 机制验证：PET显示细胞存活与功能整合 18F-FP-CIT PET是衡量多巴胺转运体（DAT）活性的金标准，直接反映移植细胞的存活和突触重建。结果显示：移植后12个月，后壳核（移植区域）的DAT结合率显著增加：高剂量组中位增长10.7%（p=0.041），低剂量组增长1.0%；更重要的是，后壳核DAT增加与关期运动评分改善呈强相关——这直接证明了移植细胞通过突触重建，恢复了多巴胺能信号传递。 A9-DPC移植后基线与12个月时的18F-FP-CIT特异性结合率（SBR）研究意义与展望：帕金森病细胞治疗的里程碑这项研究是首个进入临床阶段的人胚胎干细胞衍生的高纯度多巴胺能祖细胞（A9-DPC）疗法，其结果回答了细胞治疗帕金森病的三大关键问题：安全，无严重细胞相关不良反应；有效，高剂量组运动症状显著改善，且有机制支持；可行，GMP条件下的标准化生产可实现临床级细胞供应。研究团队下一步将开展双盲、安慰剂对照的多中心试验，纳入更多患者并延长随访时间，如果结果一致，该疗法有望为帕金森病患者带来长期缓解的希望。

2025-12-01

·帕不怕先生

截至2025年，汇总一下帕金森治疗研究的最新进展

基于近期权威研究及临床试验成果，分为六大核心方向：一、干细胞疗法：神经元再生取得突破 iPSC衍生细胞治疗 1、中国研究的进展：安徽省立医院团队通过异体iPSC分化的多巴胺神经前体细胞（NCR201）移植，使一名37岁早发型帕金森患者术后3个月实现“功能性治愈”，UPDRS评分从62分降至12分，运动功能接近常人。资料来源： https://www.163.com/dy/article/KEJAMJNF0514AD1K.html 2、全球首例快速通道资格：睿健医药的iPSC来源多巴胺前体细胞（NouvNeu001）获FDA快速通道认定，临床数据显示患者运动评分改善52.8%，非运动症状同步缓解。资料来源： https://k.sina.com.cn/article_2272376423_8771b66701901mlaq.html 3、韩国研究：延世大学开发的A9-DPCs干细胞在1/2a期试验中，高剂量组患者运动功能显著提升，PET影像证实移植细胞存活。资料来源： https://k.sina.com.cn/article_5803416260_159e91ac4019018zwe.html 胚胎干细胞应用 1、拜耳/BlueRock启动全球首个胚胎干细胞疗法BRT-DA01的Ⅲ期临床试验，旨在重建大脑神经网络。资料来源： https://k.sina.com.cn/article_2272376423_8771b66701901mlaq.html 二、基因疗法：精准靶向病理机制 AAV载体递送技术 1、AAV-GAD疗法：通过腺病毒递送谷氨酸脱羧酶基因至丘脑底核，增加抑制性神经递质GABA，改善运动症状，已获FDA再生医学高级疗法（RMAT）认证。资料来源： https://k.sina.com.cn/article_2272376423_8771b66701901mlaq.html 2、多巴胺转化酶（AADC）递送：促进脑内多巴胺合成，弥补神经元损失。资料来源： https://www.sgpjbg.com/baogao/912039.html 基因-细胞联合策略 1、士泽生物开发异体通用型iPSC产品XS411，针对早发性帕金森病开展中美临床试验，早期数据显示患者运动障碍改善超50%。资料来源： https://k.sina.com.cn/article_2272376423_8771b66701901mlaq.html 三、神经调控技术：无创与精准化升级脑机接口（BCI）临床应用 1、Neuralink实现渐冻症患者意念操控机械臂进食，该技术扩展至帕金森病运动功能修复。资料来源： https://finance.sina.com.cn/roll/2025-10-15/doc-inftymnk1936847.shtml 2、中国完成32例侵入式脑机接口植入，结合外骨骼支架改善四肢瘫痪患者运动能力。资料来源： https://www.163.com/dy/article/KDCLCPQ50514R9L4.html 经皮耳迷走神经刺激（taVNS） 1、无创调节自主神经功能，临床试验证实可降低癫痫发作频率53.8%，并改善帕金森运动症状。资料来源： https://www.163.com/dy/article/K9Q3RFB80514APJP.html 脑深部电刺激（DBS）创新 1、靶点精准化：7.0T超高场强MRI提升丘脑底核（STN）定位精度，机器人辅助电极植入误差<1.5mm。资料来源： https://news.medlive.cn/ns/info-progress/show-223236_181.html 2、新靶点探索：脚桥核（PPN）刺激改善冻结步态，联合STN-DBS提升中轴症状控制。资料来源： https://news.medlive.cn/ns/info-progress/show-223236_181.html 四、病理机制与药物研发新靶点肝-脑轴调控 1、河南大学团队发现肝源性激素FGF21通过激活FGFR1-Sirt1通路，修复血脑屏障、抑制神经炎症，减少多巴胺能神经元死亡。资料来源： https://bio.henu.edu.cn/info/1064/14797.htm 抗氧化与抗炎通路 1、虾青素证实可抑制黑质区氧化应激和NLRP3炎症小体，保护神经元。资料来源： http://physiol.bjmu.edu.cn/CN/10.20059/j.cnki.pps.2025.05.1056 2、AQP4基因多态性影响脑类淋巴系统功能，与帕金森运动进展速度直接相关。资料来源： https://www.sohu.com/a/948281382_121118801?scm=10001.325_13-325_13.0.0.5_32 多靶点营养干预 1、Kound脑醒素（含CRISPR优化成分KOXpqq）提升多巴胺分泌48%，临床改善UPDRS评分38% 资料来源： https://www.163.com/dy/article/KDM817MA0553BGPW.html 2、NEGEFO脑尼格通过纳米递送系统穿透血脑屏障，获全球五大安全认证。资料来源： https://www.jsw.com.cn/2025/1017/1925087.shtml 五、诊断与监测技术革新单细胞脑图谱 1、Duke-NUS团队绘制发育中人脑单细胞图谱（BrainSTEM），为帕金森细胞疗法提供精准蓝图。资料来源： https://news.sciencenet.cn/htmlnews/2025/11/554590.shtm 影像学生物标志物 1、DTI-ALPS指数通过弥散张量成像评估脑类淋巴功能，可预测帕金森运动进展。资料来源： https://www.sohu.com/a/948281382_121118801?scm=10001.325_13-325_13.0.0.5_32 六、中西医结合治疗策略中药创新理论 1、“熄风止颤”疗法突破传统，结合滋元固本（补肾填精）与通络化痰（清除痰湿），改善筋脉拘挛。资料来源： https://www.163.com/dy/article/KBBHUGOD0556CZN0.html 协同药物管理 1、左旋多巴缓释微球制剂降低副作用至10%，联合营养干预延长“药效蜜月期”。资料来源： https://www.163.com/dy/article/KDM817MA0553BGPW.html ----------------------------------------------------- 不知道大家有没有发现？以前谈到帕金森都说只能控制，现在整个医学界都改观了，至少变成“疾病修饰”的态度了。疾病修饰治疗（Disease-Modifying Therapy, DMT）是指通过干预疾病的核心病理机制，以延缓或阻止疾病进展、减少复发及不可逆损伤的治疗方法。与传统“对症治疗”不同，其核心目标是改变疾病自然进程，而非仅控制症状。向伟大的科学家们致敬！

基因疗法申请上市临床3期快速通道细胞疗法

2025-11-28

·PRNewswire

Pusan National University Researchers Identify Potential New Second-Line Option for Advanced Biliary Tract Cancer

Researchers find that FOLFIRINOX, a chemotherapy used for pancreatic cancer, may improve survival in advanced biliary tract cancer patients BUSAN, South Korea, Nov. 28, 2025 /PRNewswire/ -- A new collaborative study from Pusan National University and Yonsei University suggests that the FOLFIRINOX regimen showed numerically improved survival outcomes compared to current standards such as FOLFOX, FOLFIRI, and nal-IRI/FL, while maintaining manageable toxicity levels. These findings suggest that FOLFIRINOX could serve as a promising second-line treatment option for patients with advanced BTC following first-line chemotherapy failure, warranting further validation through prospective clinical studies. Continue Reading Researchers determined FOLFIRINOX may extend survival in advanced biliary tract cancer as a second-line therapy with manageable toxicity Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options remain limited once the disease progresses, after first-line chemotherapy, and survival rarely exceeds one year. To address this, the team of researchers led by Professor Yun Hak Kim from Pusan National University analyzed 12 years of clinical data from 54 patients treated at Yonsei Severance Hospital and combined the results with a systematic review and meta-analysis of 21 studies from around the world. This paper was made available online on 05 September 2025 in the journal International Journal of Surgery. The combined evidence suggests that FOLFIRINOX may provide better progression-free and overall survival than currently recommended regimens such as FOLFOX, FOLFIRI, or nal-IRI/FL. "We conducted a meta-analysis integrating 12 years of real-world data on the use of FOLFIRINOX or mFOLFIRINOX as salvage treatment in patients with advanced BTC treated at the Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, along with all available published studies on second-line chemotherapy regimens for advanced BTC," said Prof. Kim. In this study, patients receiving FOLFIRINOX achieved a median progression-free survival of 4.2 months and an overall survival of 11.4 months. In the accompanying meta-analysis of 21 studies, FOLFIRINOX demonstrated numerically longer progression-free and overall survival compared with currently used second-line regimens such as FOLFOX, FOLFIRI, and nal-IRI/FL. Still, the authors caution that toxicity remains significant. Nearly 40 percent of patients developed severe neutropenia, requiring dose adjustments or additional medical support. The team emphasizes that FOLFIRINOX should be reserved for fit patients under close supervision until further prospective trials confirm its broader safety. Beyond short-term survival, the study highlights the potential to integrate biomarker-based selection and supportive strategies such as granulocyte colony-stimulating factor to mitigate toxicity. Future research may also explore pairing FOLFIRINOX with immunotherapies or molecular-targeted drugs. "Our findings suggest that FOLFIRINOX may offer a potential benefit as a second-line treatment option for BTC following progression on first-line chemotherapy," concluded Prof. Kim. This paper provides an evidence-based foundation for clinicians considering treatment options after first-line chemotherapy failure and may guide updates to future BTC management guidelines. Reference About Pusan National University Website: About Yonsei University Media Contact: Goon-Soo Kim 82 51 510 7928 [email protected] SOURCE Pusan National University 21% more press release views with Request a Demo

临床结果免疫疗法临床研究

100 项与 Yonsei University 相关的药物交易

登录后查看更多信息

100 项与 Yonsei University 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年12月21日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Tirvalimogene Teraplasmid	头颈部鳞状细胞癌更多	临床2期
抗tRNA合成酶的抗体(Evotec) ( EPRS )	哮喘更多	临床前
ICM-203 ( NKX3-2 )	骨关节炎更多	临床前
DWJ-215	听力损失更多	临床前
PLD1 inhibitors(Yonsei University) ( PLD1 )	肺癌更多	临床前